Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$68.36 USD

68.36
256,704

-0.64 (-0.93%)

Updated Nov 6, 2024 10:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks News

Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think " Yes "

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome

Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.

DexCom (DXCM) G6 CGM System Now Available to TRICARE Members

The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.

Here's Why DexCom (DXCM) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management

DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

Style Box ETF report for IWP

Masimo's (MASI) New Product Expansion to Boost Patient Outcome

Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.

DexCom (DXCM) to Boost Diabetes Management With New Approval

DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario

Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.

Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?

Style Box ETF report for IWR

Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?

Style Box ETF report for VOT

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?

Style Box ETF report for VO

Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?

Style Box ETF report for IMCG

Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?

Style Box ETF report for IMCB

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Q4 Earnings Lag Estimates

DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH

Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.

Daniel Laboe headshot

The Markets' Tone: Cautiously Optimistic

As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Earnings Preview: DexCom (DXCM) Q4 Earnings Expected to Decline

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $435.04, marking a +1.06% move from the previous day.